HomeCompareSRRLF vs MRK

SRRLF vs MRK: Dividend Comparison 2026

SRRLF yields 5.51% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRRLF wins by $10693.45M in total portfolio value
10 years
SRRLF
SRRLF
● Live price
5.51%
Share price
$1.34
Annual div
$0.07
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$10693.51M
Annual income
$10,333,092,195.15
Full SRRLF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — SRRLF vs MRK

📍 SRRLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRRLFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRRLF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRRLF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRRLF
Annual income on $10K today (after 15% tax)
$468.15/yr
After 10yr DRIP, annual income (after tax)
$8,783,128,365.88/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, SRRLF beats the other by $8,783,120,037.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRRLF + MRK for your $10,000?

SRRLF: 50%MRK: 50%
100% MRK50/50100% SRRLF
Portfolio after 10yr
$5346.78M
Annual income
$5,166,550,996.64/yr
Blended yield
96.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

SRRLF
No analyst data
Altman Z
1.4
Piotroski
4/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRRLF buys
0
MRK buys
0
No recent congressional trades found for SRRLF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRRLFMRK
Forward yield5.51%2.76%
Annual dividend / share$0.07$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$10693.51M$56.8K
Annual income after 10y$10,333,092,195.15$9,798.13
Total dividends collected$10668.40M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SRRLF vs MRK ($10,000, DRIP)

YearSRRLF PortfolioSRRLF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,802$1,101.53$11,206$366.19+$596.00SRRLF
2$15,057$2,429.86$12,650$502.35+$2.4KSRRLF
3$21,906$5,794.83$14,407$694.19+$7.5KSRRLF
4$39,198$15,758.12$16,585$967.82+$22.6KSRRLF
5$94,646$52,704.02$19,342$1,363.89+$75.3KSRRLF
6$339,135$237,863.75$22,913$1,947.19+$316.2KSRRLF
7$1,955,983$1,593,108.89$27,662$2,823.89+$1.93MSRRLF
8$19,267,417$17,174,515.21$34,159$4,173.35+$19.23MSRRLF
9$336,835,976$316,219,839.91$43,337$6,308.80+$336.79MSRRLF
10$10,693,506,690$10,333,092,195.15$56,776$9,798.13+$10693.45MSRRLF

SRRLF vs MRK: Complete Analysis 2026

SRRLFStock

Sirius Real Estate Limited, a real estate company, engages in the investment, development, and operation of commercial properties in Germany. It owns and manages offices; warehouses, storerooms, and self-storage spaces; and production and workshop spaces. The company serves individuals and small to medium-sized enterprises under the Sirius brand name. It owns and manages business parks with approximately 4.3 million square feet of lettable space in the United Kingdom; and 1.8 million square meters of lettable space in Germany. The company was formerly known as Dawnay, Day Sirius Limited and changed its name to Sirius Real Estate Limited in October 2008. Sirius Real Estate Limited was incorporated in 2007 and is based in Saint Peter Port, Guernsey.

Full SRRLF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this SRRLF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRRLF vs SCHDSRRLF vs JEPISRRLF vs OSRRLF vs KOSRRLF vs MAINSRRLF vs JNJSRRLF vs ABBVSRRLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.